Thomas Neff, FibroGen
August 26, 2019 09:03 AM EDTUpdated 11:40 AM
R&D

Fi­bro­Gen founder and CEO Thomas Neff dies un­ex­pect­ed­ly as lead drug nears com­mer­cial thresh­old

John Carroll

Editor & Founder

Fi­bro­Gen founder and CEO Thomas Neff died “un­ex­pect­ed­ly” over the week­end, says the biotech com­pa­ny.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: FDA ap­proves Pfiz­er’s he­mo­phil­ia B gene ther­a­py, with $3.5M price tag

UCB makes ma­jor man­age­ment changes; Bris­tol My­ers’ ADC part­ner tops list of new CEOs

Gilead leans on CymaBay liv­er drug, Trodelvy read­outs and long-ac­tive PrEP yet to come this year

GSK ac­cus­es Pfiz­er and BioN­Tech of mR­NA patent in­fringe­ment

Bris­tol My­ers out­lines ‘about 12’ pipeline cuts as it ex­e­cutes ma­jor cut­backs

Up­dat­ed: Bris­tol My­ers plans $1.5B in cost cuts, in­clud­ing 2,200 jobs, as CEO promis­es more ‘ag­ile’ com­pa­ny

A service from the Financial Times